Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers: Draft Guidance. Guidance for Industry and Reviewers
Rockville, MD: U.S. Food and Drug Administration [FDA], 2002 December; 26 p. [Online]. Accessed: http://www.fda.gov/cber/gdlns/dose.pdf [2005 May 3]
Permanent LinkFind in a Library
Showing items related by title, author, creator and subject.
Guidance for Industry. Using a Centralized IRB Review Process in Multicenter Clinical Trials. Draft Guidance Unknown creator (United States. Food and Drug Administration [FDA]; Good Clinical Practice Program, Office of the Commissioner [OC]; Center for Drug Evaluation and Research [CDER]; Center for Biologics Evaluation and Research [CBER]; Office of Regulatory Affairs [ORA], 2005-03)
Guidance for Industry: Gene Therapy Clinical Trials -- Observing Participants for Delayed Adverse Events: Draft Guidance Center for Biologics Evaluation and Research [CBER] (United States) (2005-08)
Draft Guidance for Industry on Using a Centralized Institutional Review Boards Process in Multicenter Clinical Trials; Availability Unknown creator (United States. Food and Drug Administration, 2005-03-28)